NICE nod for Darzalex with lenalidomide and dexamethasone
Therapy has been developed to treat adult patients with newly diagnosed multiple myeloma
Read Moreby John Pinching | Sep 25, 2023 | News | 0
Therapy has been developed to treat adult patients with newly diagnosed multiple myeloma
Read Moreby John Pinching | Sep 6, 2023 | News | 0
Therapy is used among adult patients with symptomatic obstructive hypertrophic cardiomyopathy
Read Moreby John Pinching | Sep 4, 2023 | News | 0
The therapy has been developed for the treatment of Fabry disease among adult patients
Read Moreby Jen Brogan | Aug 22, 2023 | News | 0
Around 670 people in England with epidermolysis bullosa will benefit from the treatment
Read Moreby John Pinching | Aug 17, 2023 | News | 0
The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study
Read Moreby Jen Brogan | Aug 4, 2023 | News | 0
Therapy is a treatment option for adults with severe and moderately severe haemophilia B
Read Moreby John Pinching | Jul 3, 2023 | News | 0
The therapy becomes an option for moderate-to-severe plaque psoriasis in certain adults
Read Moreby John Pinching | Jun 7, 2023 | News | 0
Therapy treats patients with specific types of ovarian, fallopian tube or primary peritoneal cancer
Read Moreby Jen Brogan | Jun 2, 2023 | News | 0
The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15
Read Moreby John Pinching | May 18, 2023 | News | 0
The approved drug has been developed to treat patients with moderate to severe Crohn’s disease
Read Moreby John Pinching | May 15, 2023 | News | 0
NICE’s decision will result in eligible patients using a treatment that slows or halts aspects of the illness
Read Moreby John Pinching | May 3, 2023 | News | 0
Recommendation applies across England and Wales and the treatment is available now
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479